INCHEON, Korea – July 11, 2023 – Samsung Bioepis Co., Ltd. today released the second edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States. The second quarterly report details the recent price trends of all molecules for launched biosimilars including updated 2023 Q3 ASP trends and WAC trends of adalimumab biosimilars.

“So far in 2023, we have seen the start of biosimilars being launched within pharmacy benefits. This is the start of new beginning for biosimilars in the United States,” said Tom Newcomer, Vice President, Head of Market Access, US, at Samsung Bioepis. “We hope Samsung Bioepis Biosimilar Market Report brings value to healthcare stakeholders involved in the decision-making process, providing an up-to-date perspective on the US biosimilar landscape,” he added.

Samsung Bioepis Biosimilar Market Report, which was first published in April 2023, is being published every quarter after the Center of Medicare, Medicaid Services (CMS) publishes updated ASP values for each product. To access the full report, please visit HERE.

# # #

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, and endocrinology. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter, LinkedIn.

Anna Nayun Kim, nayun86.kim@samsung.com

Jane Chung, ejane.chung@samsung.com